Latest filing published 16 Jul 2026 for Galectin Therapeutics INC, €43k.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Khurram Jamil discloses dealings in Galectin Therapeutics Inc to SEC (Form 4). The record holds 32 filings, for trades running from 23 December 2024 to 14 July 2026.
No open-market purchase appears, only 18 sales worth €1.3M. The rest of the record consists of 14 option exercises. So far in 2026, the count stands at no purchases and 10 sales.
The latest filing, published on 16 July 2026, reports an open-market sale of €73k in Galectin Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations